Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Virginia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Virginia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Virginia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Michael Strachan (NPI 1982655445)

Field	Value
Entity Type	Individual
Organization	Michael Strachan
Address	7702 E Parham Rd
City	Richmond
State	VA
ZIP	23294
Taxonomy	Rheumatology Physician
NPI Enumerated	May 12, 2006

Payer Source	Total Paid
Medicare	$2.9M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-focused rheumatology practice with Total Medicare revenue of $2.9M and no Medicaid billing on file; the absence of Medicaid claims indicates a one‑payer footprint in available data rather than a mixed payer panel. The provider’s NPI has been enumerated since 2006-05-12 (~20 years ago), indicating long tenure which is consistent with an established outpatient infusion and office visit practice.

Revenue is highly concentrated in a small set of biologic infusion/drug codes: the precomputed note that the top 3 Medicare codes by revenue account for 50.9% of the provider’s Medicare revenue underscores dependence on high-cost injectable biologics as the core revenue stream. The leading single code is J3262 (tocilizumab) at $558.1K (19.3% of Medicare revenue), followed closely by J1745 (infliximab) at $539.5K (18.6%) and J0129 (abatacept) at $375.7K (13.0%), together representing the majority of billings.

The code mix and descriptions point to an operation centered on infusion-based rheumatology care: multiple high-revenue HCPCS drug codes (J3262, J1745, J0129, J1602, J0717, J9312) and chemotherapy/infusion administration codes (96413, 96401, 96415) imply in-office IV/subcutaneous biologic administration and accompanying infusion services rather than primarily procedure- or clinic-visit–only revenue. This profile suggests the practice likely maintains infusion capability and manages complex inflammatory conditions requiring biologic therapies.

Competitive standing versus national Medicare peers shows notable strengths and some extreme outliers: the provider ranks in the 99th percentile nationally for J1745 (infliximab) and in the 99th percentile for 96413 (chemotherapy infusion) — both flagged as “extreme outlier, far above typical national volume for this code” — indicating unusually high infusion/drug volume relative to peers. The provider also ranks in high percentiles for J3262 (94th) and several administration codes (e.g., 96401 at 94th, 96415 at 91st), supporting the view of an above-typical infusion-focused operation.

Other evaluation-and-management volumes are above typical national levels but are a smaller share of revenue: 99214 and 99213 together account for a modest portion of revenue ($78.1K and $54K respectively) and both rank notably high nationally (96th and 98th percentiles), suggesting the practice maintains a steady clinic visit panel to support infusion services rather than relying on E/M visits as its primary revenue driver. New-patient visits (99205) are present but small ($7.9K, 77th percentile), indicating limited high-complexity new patient volume relative to national peers.

Despite high drug and infusion volumes, several biologic and supportive codes show typical to unremarkable national volumes (for example J0129 at the 66th percentile, J9312 at the 56th percentile, and many lab/ancillary codes in mid-to-high percentiles), suggesting a mix where a few products and infusion services drive outsized revenue while other biologics and ancillary services align closer to peer norms. This pattern is consistent with a specialized infusion practice that concentrates on select biologics.

Operational risk and contracting implications: because more than half of Medicare revenue is concentrated in a small number of high-cost J‑codes (top 3 = 50.9%), changes in drug pricing, reimbursement, or payer utilization management for those specific agents (notably J3262 and J1745) could materially affect revenue. Payors and network managers should treat this provider as a targeted infusion network participant when evaluating reimbursement strategies or prior authorization processes.

Geographic and scale context: the provider is located in RICHMOND, VA and shows no Medicaid claims on file, so state Medicaid negotiating leverage is likely minimal or absent; commercial and Medicare Advantage contracting strategies should reflect that Medicare constitutes the observable payer base and that the practice demonstrates above-average national throughput for certain infusion therapies.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

31 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3262	Injection, tocilizumab, 1 mg	111,630	$10	$558.1K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	20,750	$30	$539.5K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	11,050	$30	$375.7K
J1602	Injection, golimumab, 1 mg, for intravenous use	31,730	$10	$317.3K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	78,000	$1	$312K
J9312	Injection, rituximab, 10 mg	3,600	$60	$216K
J0897	Injection, denosumab, 1 mg	8,220	$20	$148K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	3,230	$40	$113K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,080	$100	$105.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	830	$90	$78.1K

Showing 1–10 of 31

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 31 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Virginia Distribution

Michael Strachan — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Virginia

Full comparison — all codes billed, vs. state median

31 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	14	30	10,450	$30	$407.3K
J3262	2	20	75,870	$1	$383.3K
J0717	15	30	74,500	$1	$361.7K
J9312	3	10	3,950	$60	$259.5K
J1745	4	30	4,540	$30	$200.2K
J1602	3	20	13,430	$10	$176.7K
J0897	53	340	2,820	$20	$89.3K
Q5115	1	10	2,110	$30	$75K
96413	2	230	250	$100	$28.5K
99214	720	12,890	140	$80	$21K

Showing 1–10 of 31

Related Providers

Other providers that share a Tax Identification Number (TIN) with Michael Strachan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Tammy Spring	VA	Rheumatology Physician	$1.3M	$0
Mihail Moroianu	VA	Rheumatology Physician	$732K	$0
Bhakti Joshi	VA	Rheumatology Physician	$152.3K	$0
Avnit Ahuja	VA	Rheumatology Physician	$116K	$0

Nearby Providers

Other providers in the same ZIP code as Michael Strachan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Behavioral Health Services Of Virginia Corporation	VA	Community/Behavioral Health Agency	$0	$25.1M
Aaa Home Health Care LLC	VA	Home Health Agency	$0	$13.8M
River City Comprehensive Counseling Services, LLC	VA	Community/Behavioral Health Agency	$0	$10.7M
Commonwealth Radiology P C	VA	Diagnostic Radiology Physician	$0	$9.6M
Insight Physicians PC	VA	Psychiatry Physician	$0	$8.4M
River City Comprehensive Counseling Services, LLC	VA	Community/Behavioral Health Agency	$0	$7.4M
Family Focus, LLC	VA	Case Management Agency	$0	$7.3M
Pony-care Transportation, Inc	VA	Non-emergency Medical Transport (VAN)	$0	$6.7M
David Carleton	VA	Rheumatology Physician	$4.3M	$0
Steven Maestrello	VA	Rheumatology Physician	$1.1M	$0

Michael Strachan — Billing Profile & Reimbursement Data

Sign up for Michael Strachan — Billing Profile & Reimbursement Data policy alerts

Michael Strachan — Billing Profile & Reimbursement Data

Sign up for Michael Strachan — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References